CytoDyn Inc. (OTCMKTS:CYDY) Short Interest Up 15.0% in January

CytoDyn Inc. (OTCMKTS:CYDY - Get Free Report) was the target of a large growth in short interest in January. As of January 15th, there was short interest totalling 20,123,400 shares, a growth of 15.0% from the December 31st total of 17,499,100 shares. Based on an average trading volume of 6,176,200 shares, the short-interest ratio is currently 3.3 days.

CytoDyn Price Performance

Shares of CytoDyn stock traded up $0.01 during trading hours on Tuesday, hitting $0.21. The company had a trading volume of 2,466,175 shares, compared to its average volume of 4,043,476. The company's 50-day moving average is $0.15 and its two-hundred day moving average is $0.14. The company has a market cap of $257.58 million and a P/E ratio of -20.98. CytoDyn has a twelve month low of $0.10 and a twelve month high of $0.32.

About CytoDyn

CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.